✦ LIBER ✦

Mitoxantrone and etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia

✍ Scribed by M. Lazzarino; E. Morra; E. P. Alessandrino; E. Orlandi; G. Pagnucco; S. Merante; P. Bernasconi; D. Inverardi; M. Bonfichi; C. Bernasconi

Book ID: 114791113
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 413 KB
Volume: 43
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1989.tb00328.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone and high-dose etoposide for

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia

✍ Susan O'Brien; Kantarjian Hagop; Elihu Estey; Charles Koller; Miloslav Beran; Ke 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Mitoxantrone for refractory and relapsed

Mitoxantrone for refractory and relapsed acute leukemia

✍ Werner R. Bezwoda; Cano Bernasconi; Robert M. Hutchinson; David A. Winfield; Rob 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB 👁 2 views

Mitoxantrone in relapsed or refractory a

Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia

✍ Vredenburgh, James J. ;McLntyre, O. Ross ;Cornwell, Gibbons G. ;Ball, Edward D. 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB

Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days. If the day fourteen bone marrow showed residual leukemia, a second course was given at the same dose for two days. Eight patient

Sorafenib as treatment for relapsed or r

Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

✍ Tanya C. Watt; Todd Cooper 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Comparison of fludarabine-containing sal

Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia

✍ Thomas, M B; Koller, C; Yang, Y; Shen, Y; O'Brien, S; Kantarjian, H; Davis, J; E 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 109 KB

Mitoxantrone, etoposide, and cytarabine

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia : An Eastern Cooperative Oncology Group pilot study

✍ Martin S. Tallman; Sandra Lee; Branimir I. Sikic; Elisabeth Paietta; Peter H. Wi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Background: One potential mechanism of drug resistance to chemotherapy is the overexpression of multidrug resistance (mdr) genes coding for p-glycoprotein (p-gp), which leads to reduced intracellular retention of chemotherapy. this study tested the efficacy and toxicity of mitoxantrone, etoposid